National Academies Press: OpenBook

Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism (2001)

Chapter: Appendix B: March 8, 2001 - Meeting Agenda

« Previous: Appendix A: Januaray 11, 2001 - Meeting Agenda
Suggested Citation:"Appendix B: March 8, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×

Page 75

APPENDIX B

March 8, 2001
Meeting Agenda

IMMUNIZATION SAFETY REVIEW COMMITTEE MEASLES-MUMPS-RUBELLA VACCINE AND AUTISM MEETING

National Academies Building

2101 Constitution Ave., NW

Washington, D.C.

SESSION I: ETIOLOGY, DIAGNOSIS, AND EPIDEMIOLOGY OF AUTISM

8:30–8:35 a.m.

Opening Remarks

Marie McCormick, M.D., Sc.D., Chair, Immunization Safety Review Committee

8:35–9:00 a.m.

Neurobiology and Neuropathology of Autism

Thomas Kemper, M.D., Professor, Department of Neurology, Anatomy, and Pathology, Boston University School of Medicine

9:00–9:30 a.m.

Etiology of Autism and NIH Research

Marie Bristol-Power, Ph.D., Special Assistant on Autism, Office of the Director, National Institute of Child Health and Human Development, National Institutes of Health

Suggested Citation:"Appendix B: March 8, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×

Page 76

9:30–10:00 a.m.

Diagnosis and Assessment of Autism

Fred Volkmar, M.D., Professor of Child Psychiatry, Pediatrics, and Psychology, Yale Child Study Center

10:15–10:45 a.m.

Epidemiological Evidence on Rates of Autism and Time Trends

Eric Fombonne, M.D., FRCPsych, Reader in Epidemiological Child Psychiatry, Institute of Psychiatry, King's College London

10:45–11:00 a.m.

Trends in Students with Autism in IDEA Programs

Louis Danielson, Ph.D., Director of Research to Practice Division, Office of Special Education Programs, Department of Education

11:00–11:45 a.m.

Discussion Panel

Kathryn Carbone, M.D., Chief, Laboratory of Pediatric and Respiratory Viral Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration

Karin Nelson, M.D., Senior Investigator, Neuroepidemiology Branch, National Institute for Neurological Disorders and Stroke, National Institutes of Health

Ezra Susser, M.D., Head, Division of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University

SESSION II: MMR AND AUTISM HYPOTHESIS

12:30–1:30 p.m.

Hypothesis and Data Linking MMR, Bowel Symptoms and Autism

Andrew Wakefield, M.D., Royal Free & University College Medical School, United Kingdom

Kenneth Aitken, Ph.D., Independent Consultant Child Clinical Neuropsychologist

1:30–2:00 p.m.

Overview of Epidemiological Studies Examining Potential Link Between MMR, Bowel Symptoms, and Autism

Michael Stoto, Ph.D., Chair, Department of Epidemiology and Biostatistics, George Washington University

2:00–2:30 p.m.

New Data and Research Findings Regarding a Potential Link Between MMR, Bowel Symptoms, and Autism

Suggested Citation:"Appendix B: March 8, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×

Page 77

 

Eric Fombonne, M.D., FRCPsych, Reader in Epidemiological Child Psychiatry, Institute of Psychiatry, King's College London

2:45–4:00 p.m.

Discussion Panel

Scott Montgomery, Ph.D., Karolinska Institute, Sweden

Brian Ward, M.D., Associate Professor, Medicine & Microbiology, McGill University and Montreal General Hospital Research Institute

Michael Gershon, M.D., Professor and Chair, Department of Anatomy and Cell Biology, Columbia University

Kathryn Carbone, M.D., Chief, Laboratory of Pediatric and Respiratory Viral Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration

Karin Nelson, M.D., Senior Investigator, Neuroepidemiology Branch, National Institute for Neurological Disorders and Stroke, National Institutes of Health

4:00–4:15 p.m.

Study of Autism and the Vaccine Adverse Event Reporting System (VAERS)

Jane Woo, M.D., M.P.H., Fellow, Vaccine Safety Branch, Division of Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration

4:15–5:00 p.m.

Public Comment Session

Suggested Citation:"Appendix B: March 8, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×

Page 78

Suggested Citation:"Appendix B: March 8, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×
Page 75
Suggested Citation:"Appendix B: March 8, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×
Page 76
Suggested Citation:"Appendix B: March 8, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×
Page 77
Suggested Citation:"Appendix B: March 8, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×
Page 78
Next: Appendix C: Immunization Safety Review Committee Biosketches »
Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism Get This Book
×
Buy Paperback | $35.00 Buy Ebook | $27.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Immunization is widely regarded as one of the most effective and beneficial tools for protecting the public's health. In the United States, immunization programs have resulted in the eradication of smallpox, the elimination of polio, and the control and near elimination of once-common, often debilitating and potentially life-threatening diseases, including measles, mumps, rubella, diphtheria, pertussis, tetanus, and Haemophilus influenza type b.

Along with the benefits of widespread immunization, however, have come concerns about the safety of vaccines. No vaccine is perfectly safe or effective, and vaccines may lead to serious adverse effects in some instances. Furthermore, if a serious illness is observed after vaccination, it is often unclear whether that sequence is coincidental or causal, and it can be difficult to determine the true nature of the relationship, if any, between the vaccination and the illness. Ironically, the successes of vaccine coverage in the United States have made it more difficult for the public to weigh the benefits and complications of vaccines because the now-controlled diseases and their often-serious risks are no longer familiar. However, because vaccines are so widely used-and because state laws require that children be vaccinated before entering daycare and school, in part to protect others-it is essential that safety concerns be fully and carefully studied.

Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism, the first of a series from the Institute of Medicine (IOM) Immunization Safety Review Committee, presents an assessment of the evidence regarding a hypothesized causal association between the measles-mumps-rubella (MMR) vaccine and autism, an assessment of the broader significance for society of the issues surrounding the MMR-autism hypothesis, and the committee's conclusions and recommendations based on those assessments.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!